Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : WHO praises AstraZeneca COVID-19 vaccine trial pause

share with twitter share with LinkedIn share with facebook
09/15/2020 | 06:01am EDT

A World Health Organization official on Tuesday said that the decision by AstraZeneca to pause global trials of its experimental coronavirus vaccine after an unexplained illness showed the firm was prioritising safety.

"This is what we want to see with trials, it is a well-run trial. Safety is always critical, it is crucial and they have looked at that in an appropriate manner," Margaret Harris told journalists in Geneva.

Asked to react to experimental COVID-19 vaccine use in China and Russia, she said: "The WHO would like to see vaccines go head to head so we can have clear information and to see these results against each other."

(Reporting by Emma Farge, editing by Louise Heavens)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.20% 8576 Delayed Quote.12.74%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.15% 77.99 Delayed Quote.23.82%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/25Canada's biggest provinces seek clampdown on social gatherings as coronavirus..
RE
09/25Europe takes new action against Apple, Boeing’s 737 MAX flying soon?
09/25What you need to know about the coronavirus right now
RE
09/25EXCLUSIVE : AstraZeneca gets partial immunity in low-cost EU vaccine deal
RE
09/25AstraZeneca gets partial immunity in low-cost EU vaccine deal
RE
09/25Eu paid lower price for astrazeneca vaccine in return for partial liability -..
RE
09/25Astrazeneca granted partial shield against side-effect claims in eu covid vac..
RE
09/25NOVAVAX : initiates late-stage COVID-19 vaccine trial in UK
RE
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
RE
More news
Financials (USD)
Sales 2020 26 694 M - -
Net income 2020 3 079 M - -
Net Debt 2020 13 082 M - -
P/E ratio 2020 50,6x
Yield 2020 2,58%
Capitalization 143 B 143 B -
EV / Sales 2020 5,86x
EV / Sales 2021 5,14x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 117,86 $
Last Close Price 109,30 $
Spread / Highest target 42,2%
Spread / Average Target 7,83%
Spread / Lowest Target -39,6%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC12.74%142 957
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402